Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2025.101.08
- Author:
Xinyue YANG
1
;
Zhiwei TANG
2
;
Li MA
3
;
Ran CHEN
1
Author Information
1. Department of Oncology, Postgraduate Union Training Base of Xiangyang No.1 People's Hospital, School of Medicine, Wuhan
University of Science and Technology, Xiangyang 441000, China.
2. Department of Oncology, Xiangyang No.1 People's Hospital,
Hubei University of Medicine, Xiangyang 441000, China.
3. Department of Medical Oncology, Beijing Chest Hospital,
Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
- Publication Type:English Abstract
- Keywords:
Immune checkpoint inhibitors;
Immunotherapy;
KRAS mutation;
Lung neoplasms
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/immunology*;
Lung Neoplasms/immunology*;
Proto-Oncogene Proteins p21(ras)/immunology*;
Immunotherapy/methods*;
Mutation;
Animals
- From:
Chinese Journal of Lung Cancer
2025;28(5):343-352
- CountryChina
- Language:Chinese
-
Abstract:
In epidemiological statistics, the incidence rate and mortality rate of malignant lung tumors rank among the top. Non-small cell lung cancer (NSCLC) constitutes an important part of lung cancer and has become a key focus of clinical research and treatment. Among the genomic characteristics of NSCLC, the Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is one of the main tumor drivers, accounting for approximately 25% of all NSCLC cases. The existence of this mutation is closely related to the treatment response and prognosis of patients. Therefore, the treatment strategy for KRAS-mutated NSCLC is an important topic in the field of tumor research. In the current era, immunomodulatory therapy has rapidly gained popularity and developed rapidly in oncology due to its unique mechanism of action and remarkable clinical efficacy. The treatment strategies targeting the KRAS-mutated of NSCLC have gradually become a research hotspot. The advent of immune checkpoint inhibitors (ICIs) has opened up a new therapeutic avenue for patients with such cancers, and clinical studies have shown significant effects in improving survival rates. Nevertheless, there are still many challenges in the application of immunotherapy, such as the complexity of the tumor microenvironment, individual differences among patients, and drug resistance mechanisms. This article reviews the progress of immunotherapy for KRAS-mutated NSCLC, focusing on the specific application of immunotherapy, the exploration of combination therapies, and the results of related clinical trials. At the same time, it discusses the possible future development directions of KRAS-mutated NSCLC treatment, providing a reference for clinical treatment practice.
.
